ARQ 621
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Trial Timeline
Aug 1, 2009 → Sep 1, 2011
NCT ID
NCT00825487About ARQ 621
ARQ 621 is a phase 1 stage product being developed by Merck for Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00825487. Target conditions include Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00825487 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies